南非比勒陀利亚大学研发出新型皮肤替代产品 中新网约翰内斯堡9月12日电 南非广播公司12日报道称，南非比勒陀利亚大学新研发出一种新型皮肤替 代产品"无细胞真皮支架(ADS)"，为未来3D生物打印天然皮肤铺平道路，成为传统皮肤移植的替代方 案。 该研究负责人哈菲扎·帕卡尔(Doctor Hafiza Parkar)介绍，无细胞真皮支架是一种用于严重创口的皮肤替 代产品，能够模拟人体皮肤，在动物实验中已显示出加速愈合的效果。 帕卡尔说，它的作用是为机体提供一个框架，以便长出新的健康组织。动物实验显示，它能减少移植中 常见的排斥反应，同时加快愈合速度，对于烧伤、溃疡等复杂创面尤其有效。(完) 来源：中国新闻网 编辑：陈俊明 广告等商务合作，请点击这里 本文为转载内容，授权事宜请联系原著作权人 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"jwview")，看更多精彩财经资讯。 ...

Core Viewpoint - The article highlights the achievements of 35 innovators under the age of 35 in various fields such as climate and energy, artificial intelligence, biotechnology, computing, and materials science, showcasing their groundbreaking contributions and potential impact on their respective industries [6][11][60]. Climate and Energy - Innovators in this sector are developing advanced technologies for decarbonization, with applications across shipping, fashion, and other industries. They are also exploring new methods for sustainable energy and innovative uses for carbon capture [11]. - Iwnetim Abate is working on producing ammonia using underground heat and pressure, aiming to reduce carbon emissions associated with traditional ammonia production, which contributes 1% to 2% of global CO2 emissions [13]. - Sarah Lamaison's company, Dioxycle, is developing a method to produce chemicals using electricity instead of fossil fuels, significantly reducing greenhouse gas emissions [16][17]. - Gaël Gobaille-Shaw's Mission Zero focuses on direct air capture technology to extract CO2 from the atmosphere, while his second company, Supercritical, aims to produce hydrogen efficiently [19][20]. Artificial Intelligence - Aditya Grover has developed ClimaX, an AI model that predicts weather and climate events, utilizing extensive datasets for improved accuracy [22][23]. - Neel Nanda is researching the interpretability of AI models to ensure their safe and beneficial development, focusing on understanding the decision-making processes of these models [34][35]. - Mark Chen has led advancements in AI models for image processing and code generation, contributing to the development of OpenAI's DALL·E and Codex [38][39]. - Akari Asai is working on retrieval-augmented generation technology to reduce AI hallucinations by allowing models to reference stored data before generating responses [51][52]. Biotechnology - Christian Kramme's company, Gameto, is developing artificial ovarian technology to assist IVF patients, aiming to reduce hormonal injections and stress during the process [62][63]. - Kevin Eisenfrats founded Contraline to create a long-lasting male contraceptive gel, with ongoing clinical trials to validate its effectiveness [64][65]. Computing and Materials Science - Pierre Forin's company, Calcarea, is developing a system to capture and store CO2 emissions from ships, with plans for commercial deployment by 2027 or 2028 [28][29]. - Neeka Mashouf's Rubi Laboratories is innovating a method to produce textiles by extracting CO2 directly from the atmosphere, aiming for sustainable fashion solutions [25][26].

Core Insights - Beijing Saiweisen International Biotechnology Co., Ltd. launched the brand "Yue Mijing," redefining women's intimate care standards through innovative solutions backed by patented technologies [1][2] - The company emphasizes supply chain management and quality control, sourcing key raw materials from biotech firms with proprietary technologies [1] - The growth of the "she economy" and the increasing health awareness among women, particularly those born in the 90s and 00s, are driving the expansion of the female consumer market [1] Product Innovation - The "Yue Mijing" antibacterial solution addresses industry pain points by utilizing "temperature-sensitive phase change technology," allowing the product to transition from liquid to gel at body temperature [2] - Clinical tests indicate that the product effectively inhibits bacteria such as Staphylococcus aureus and E. coli while being naturally expelled from the body, a feature lacking in existing products [2] - The product's formulation includes a proprietary blend of herbal extracts, enhancing its antioxidant, anti-inflammatory, and antibacterial properties [2] Market Context - The intimate care product market shows a significant demand, with intimate care liquids accounting for 48.8% of the market share, yet traditional products face challenges in absorption efficiency and safety [1] - Analysts highlight that many existing products suffer from a lack of research and development focus, contrasting with Saiweisen's commitment to innovation and collaboration with clinical experts [2]

Core Viewpoint - The stock price of Pioneer Pharma Biotechnology (0399.HK) experienced a significant drop of 22.12% to HKD 0.405, marking a nearly two-month low since July 21 [1] Group 1: Company Announcement - Pioneer Pharma announced a placement agreement with China Northern Securities Group, set for August 21, 2025, to issue up to 145 million shares at a placement price of HKD 0.415 per share [1] - The board declared that the placement agreement became invalid as the conditions precedent were not met by September 11, 2025, resulting in the cancellation of the placement [1] Group 2: Financial Implications - The company had previously announced on August 21 that it aimed to raise HKD 58.825 million from the placement of 145 million shares, with the proceeds intended for funding the development of its blockchain technology business [1] - Following the announcement of the placement on August 22, the stock surged by 10.87% [1]

Core Insights - The U.S. Labor Department reported that the Consumer Price Index (CPI) rose by 2.9% year-on-year in August, while the core CPI increased by 3.1%, aligning with market expectations, which strengthens the market's bets on a potential interest rate cut by the Federal Reserve [1] Group 1: Market Implications - A potential interest rate cut could lead to a weaker U.S. dollar, which may drive capital back to emerging markets, benefiting the Hong Kong stock market that has a high proportion of foreign investment [1] - The technology sector, being liquidity-sensitive, is likely to be the first to benefit from expectations of monetary easing [1] Group 2: Sector Analysis - A shift towards a looser interest rate environment would help reduce financing costs for technology companies in Hong Kong, particularly in high R&D sectors like biotechnology and the internet, alleviating pressure on valuation discount rates and improving long-term profit expectations [1] - Additionally, a rate cut may stimulate a rise in global risk appetite, enhancing market sentiment for the technology growth sector [1] - Technology companies, known for their resilience and growth attributes, tend to exhibit stronger upside potential in a loose monetary environment [1] Group 3: Investment Vehicles - Relevant ETFs for the Hong Kong technology sector include the Hong Kong Stock Connect Technology ETF (159101) and the Hang Seng Internet ETF (513330) [1]

Market Performance - The Hang Seng Index rose by 1.53% at midday on the 12th [2] - The Hang Seng Tech Index increased by 2.18% [2] - The Hong Kong Stock Connect ETF (159318) gained 0.77% [2] - The Hong Kong Tech ETF (159751) saw an increase of 0.94% [2] Sector Performance - The metals and mining sector, along with the machinery manufacturing sector, showed strong gains [2] - The diversified REITs and biotechnology sectors experienced the largest declines [2] Individual Stock Movements - Baidu Group-SW surged by 8.54% [2] - China Hongqiao increased by 6.06% [2] - Alibaba-WR rose by 6.03% and Alibaba-W by 5.93% [2] - China Aluminum gained 5.92% [2] - Luoyang Molybdenum rose by 5.28% [2] - Kangfang Biotech increased by 4.38% [2] - Yimeng Biotech-B fell by 5.18% [2] - Hongteng Precision Technology dropped by 5.47% [2] - Yaojie Ankang-B surged over 55% [2] - Evergrande Property increased by 30.43% [2]

Core Viewpoint - The study presents a novel method for real-time diagnosis of cholangiocarcinoma (CCA) by combining optical fiber biosensors based on bile clusterin with digestive endoscopy, addressing the urgent need for improved diagnostic techniques for this aggressive cancer type [2][10]. Summary by Sections Diagnosis Challenges - Cholangiocarcinoma is a highly malignant tumor with a poor prognosis, characterized by late diagnosis due to non-specific early symptoms, resulting in a 5-year survival rate of only 7%-20% [2]. Research Findings - The research team identified clusterin (CLU) as a promising biomarker for CCA through proteomic analysis of bile and cell supernatants, highlighting its overexpression in various cancers [5]. - The optical fiber biosensor technology, particularly surface plasmon resonance (SPR), was utilized for its high sensitivity and stability in detecting biological markers [5]. Methodology - The study involved 583 subjects and two rounds of proteomic analysis to screen and validate biomarkers for CCA, leading to the development of an SPR-based optical fiber biosensor [6]. - The biosensor demonstrated a high correlation coefficient of 0.989 and could accurately detect varying concentrations of CLU, with a detection time of 2 seconds and an area under the curve (AUC) of 0.854 [7]. Clinical Application - The CLU optical fiber biosensor was successfully integrated with digestive endoscopy, allowing for real-time in vivo diagnosis of CCA, with results aligning with postoperative pathology findings in patients [8][10].

Core Insights - Absci (ABSI.US) announced a collaboration with Oracle (ORCL.US) and AMD (AMD.US) to accelerate AI-driven drug development [1] - The partnership will utilize Oracle's AI infrastructure and AMD's hardware in Absci's generative AI Drug Creation Platform [1] - The CEO of Absci emphasized that this collaboration will enhance the efficiency of delivering new therapies to patients and establish a technological foundation for next-generation AI-driven drug development processes [1] Company Developments - Absci is based in Vancouver, Washington, and focuses on biotechnology [1] - The announcement coincided with the Oracle Health and Life Sciences Summit held from September 9 to 11 in Orlando, Florida [1] - At the summit, Oracle showcased advancements in healthcare technology, including AI capabilities in its Oracle Fusion Cloud Application, aimed at streamlining supply chain operations in the healthcare industry [1]

Core Insights - The report highlights the performance of the Hong Kong stock market, with the Hang Seng Index at 26,086 points, reflecting a year-to-date increase of 30.0% despite a daily decline of 0.4% [3] - The report discusses the impact of macroeconomic factors, including the recent interest rate adjustments by the People's Bank of China and ongoing trade tensions between China and the U.S., which are expected to influence market conditions in the short to medium term [10][11] - The report provides a detailed analysis of the performance of individual stocks within the Hang Seng Index, noting significant gains for companies like SMIC and China Hongqiao, while highlighting losses for companies such as Hansoh Pharmaceutical [4][25] Market Overview - The Hang Seng Index has seen a trading volume of HKD 3,252.1 billion, with a price-to-earnings (PE) ratio of 11.9 and a price-to-book (PB) ratio of 1.22 [5] - The report notes that the H-share index and technology index also experienced declines, with the H-share index at 9,260 points, down 0.7% for the day and up 27.0% year-to-date [3][11] - The report indicates that the A-share market has shown positive performance, with the Shanghai Composite Index rising to 3,875 points, an increase of 1.7% [13] Company Performance - Galaxy Entertainment reported a year-on-year revenue increase of 8.3% to HKD 23.25 billion, with adjusted EBITDA rising 14.2% to HKD 6.87 billion, and a net profit increase of 19.4% to HKD 5.24 billion [25][26] - The report details the revenue breakdown for Galaxy Entertainment, noting a 10.7% increase in gaming operations revenue, while hotel and shopping center revenues grew by 2.5% [25] - The company's total assets are approximately HKD 94.8 billion, with total liabilities decreasing by 18.9% to HKD 14.7 billion, indicating a strong balance sheet [26] New Stock Dynamics - The report outlines upcoming IPOs, including Health 160 and Jinfang Pharmaceutical-B, with expected market interest due to their moderate fundraising sizes and potential for high demand [30][31] - The report provides insights into the pricing and expected market performance of these new listings, suggesting a favorable environment for new stock offerings [31]

Group 1 - In recent years, several provinces in China, including Sichuan, Henan, Jiangxi, and Shaanxi, have seen changes in their wealth rankings, with new billionaires emerging as the richest individuals in these regions [1][2] - Wang Ning, the founder of Pop Mart, has surpassed Qin Yinglin and Qian Ying, becoming the richest person in Henan with a wealth of $23 billion, ranking 96th globally according to Forbes [1] - Pop Mart reported a revenue of 13.88 billion yuan in the first half of 2025, a year-on-year increase of 204.4%, and an adjusted net profit of 4.71 billion yuan, up 362.8% [1] Group 2 - Chen Tian Shi, founder of Cambrian, has become the new richest person in Jiangxi, with a wealth of $21.5 billion, significantly surpassing the previous richest, Luo Yuhao, whose wealth is $4.3 billion [2] - Cambrian's stock price has surged due to the booming Chinese chip industry, reaching a market capitalization of 663.7 billion yuan, briefly overtaking Kweichow Moutai as the top stock in A-shares [2] - Both Wang Ning and Chen Tian Shi are part of the younger generation of entrepreneurs, born in the 1980s, and are leading figures in the emerging consumer and chip industries [2] Group 3 - In Shaanxi, the couple Fan Daidi and Yan Jianya from Juzhi Biotechnology have become the new richest individuals, with a wealth of $5.1 billion, surpassing the previous richest, Li Zhenguo and Li Xiyan, who have a wealth of $3.5 billion [4] - The wealth of Zhu Yi, the actual controller of Baili Tianheng, has increased significantly, with his shares valued at over 115 billion yuan, making him the richest in Sichuan [2][3]